Text size Maddie Meyer / Getty Images Moderna’s shares have risen 239% so far this year, and the biotech company, which has no approved medications, has a market capitalization of more than $ 24 billion. But in a note sent out Monday morning, Jefferies analyst Michael Yee writes that the …
Read More »Moderna’s stock falls due to the report of the delay in the Covid-19 vaccine trial
Text size Joseph Prezioso / Getty Images Shares of Modern biotechnology fell 6.2% on Thursday afternoon after health news website Stat reported that the company was delaying the start of a Phase 3 trial of its experimental Covid-19 vaccine. The report, based on quotes from unidentified sources described as “investigators,” …
Read More »Pfizer’s shares rise as the company reveals the timeline for the coronavirus vaccine.
Text size Daniel Acker / Bloomberg Shares of the large pharmaceutical company Pfizer continue to rise one day after the company revealed promising and detailed data on a trial of its experimental vaccine Covid-19. Analysts said the highly aggressive timeline the company outlined on Wednesday was exciting, but far from …
Read More »Intercept actions fall on NASH disappointment
Text size Dirk Waem / Getty Images NASH was once the next big thing for big drug companies; a newly defined disorder that requires chronic treatment that affects millions of people in developed countries. Dozens of companies are developing drugs for the disease, which can cause life-threatening conditions like decompensated …
Read More »Moderna is the latest partner in the coronavirus vaccine for Catalent
Text size Joseph Prezioso / AFP via Getty Images Moderna said it has partnered with Catalent to make the Covid-19 vaccine that the biotech company is about to test in the country’s first major clinical trial. Although the vaccine’s large-scale safety and efficacy have not yet been proven, the urgency …
Read More »